CYP2C19 and Parkinson disease: Similarly, genetic polymorphisms in enzymes such as CYP2D6 and CYP2C19 affect drug metabolism in PD patients, influencing the efficacy and tolerability of dopamine agonists and other therapies (Haass and Selkoe, 2007; Tobe and Jurisic, 2018).